1. Iluvien, Summary of Product Characteristics.
2. National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). NICE technology appraisal guidance 301, 2013. Available at: www.nice.org.uk/guidance/ta301. [Accessed October 2017]
3. Bailey C, et al. Real-world experience with 0.2μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 21st July 2017. [Epub ahead of print]. Available at: http://www.nature.com/eye/journal/vaop/ncurrent/full/eye2017125a.html?fo...
4. National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. Technology appraisal guidance [TA346], 2015. Available at: https://www.nice.org.uk/guidance/ta346/chapter/1-Guidance [Accessed October 2017]
5. National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema. Technology appraisal guidance [TA274], 2013. Available at: https://www.nice.org.uk/guidance/ta274/chapter/1-Guidance
6. Campochiaro PA, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125-2132.
7. Quhill F, Beiderbeck A. Cost advantage of fluocinolone acetonide implant (ILUVIEN) versus ranibizumab in the treatment of chronic diabetic macular oedema. Global & Regional Health Technology Assessment. 2017;4(1):e155-e164.